Skip to content
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
Search
Join Pα+
  • My Pα+
  • Sign In
Menu
  • My Pα+
  • Sign In
Pα+
  • My Pα+
  • Sign In
  • My Pα+
  • Sign In
Search
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
Menu
  • Insights
  • Data
  • Advisory
  • Careers
  • Feed
Read more about the article Reset Pharmaceuticals Enters into Exclusive Worldwide License Agreement with NYU Langone Health for Intellectual Property and Data on Psilocybin and Related Psychedelics for the Treatment of Mental Illness in Patients with Life-Threatening Diseases, Including Cancer

Reset Pharmaceuticals Enters into Exclusive Worldwide License Agreement with NYU Langone Health for Intellectual Property and Data on Psilocybin and Related Psychedelics for the Treatment of Mental Illness in Patients with Life-Threatening Diseases, Including Cancer

  • Post published:July 7, 2021
  • Post category:Press Release

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

  • Insights
  • Jobs
  • Data
  • Subscribe to Pα+
  • Contact

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.

Subscribe to Pα+
  • Psychedelic Alpha © 2025, All Rights Reserved
  • Privacy Policy
  • Terms of Service

Subscribe to Our Free Newsletter

Join Pα+ for Premium Insights

Subscribe Annually ($200)
Subscribe Monthly ($20)
Learn More